NCT05101551 2026-04-22
PARPAML
Stanford University
Phase 1 Recruiting
Clinical Trials
7 trialsNCT03974217 2026-02-25
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04207190 2024-11-01
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT06218628 2024-05-03
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
Phase 1 Recruiting
NCT05319249 2024-04-05
NAKIP-AML
German Cancer Research Center
Phase 1/2 Not yet recruiting
NCT02878785 2023-03-29
1565GCC
University of Maryland, Baltimore
Phase 1/2 Completed
NCT01399840 2017-09-15
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Pfizer
Phase 1 Completed